Study identification

PURI

https://redirect.ema.europa.eu/resource/50613

EU PAS number

EUPAS44024

Study ID

50613

Official title and acronym

ImPact of comoRbidity In Severe asthMa patients (PRISM)

DARWIN EU® study

No

Study countries

Argentina
Australia
Bulgaria
Canada
Colombia
Denmark
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Portugal
Saudi Arabia
Spain
Taiwan
United Arab Emirates
United Kingdom
United States

Study status

Planned
Research institutions and networks

Institutions

Networks

Respiratory Effectiveness Group (REG)
Belgium
Denmark
France
Germany
Greece
Hungary
Italy
Netherlands
Spain
Sweden
United Kingdom
First published:
04/06/2024
Network
ENCePP partner

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, OPC Global
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable